Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks .

Recent Articles

Slack Stock Is At an Inflection Point And Looks Expensive Here

By Mark R. Hake, CFA Aug 31, 2020

Slack is at an inflection point with growing free cash flow. Slack stock assumes sales will grow over 33% annually over the next 3 years.

5 Cheap Stocks to Buy With High Yield and Good Earnings Power

By Mark R. Hake, CFA Aug 28, 2020

These high-yield stocks also provide great earnings power. That said, all five of these names represent some of the top cheap stocks to buy.

Microsoft Gets Stronger as Free Cash Flow Grows

By Mark R. Hake, CFA Aug 27, 2020

Microsoft goes from strength to strength as its free cash flow grows. MSFT stock will hit $2 trillion, or $263.62, based on a 3% FCF yield and similar FCF growth as last year.

Do Not Chase Tesla Stock After It Rallied 50%

By Mark R. Hake, CFA Aug 27, 2020

Tesla stock shot up on news of its 5-for-1 stock split, but investors are better off waiting for a pullback or correction to buy shares.

Ocugen Stock Looks Like a Really Good Short Candidate Here

By Mark R. Hake, CFA Aug 27, 2020

There's a good deal of downside risk, but Ocugen is worth a look. OCGN stock is likely to fall as Ocugen raises $30 million or 54% of its equity to fund operations over the next 2 plus years.